How Hybrid Closed-Loop Systems Help People with Type 1 Diabetes

Living with Type 1 diabetes means making constant adjustments. Every meal, workout, illness, stressful day, or change in routine requires tweaking insulin doses. This relentless math, combined with the fear of low blood sugar, can lead to anxiety, depression, and diabetes burnout.

Despite doing everything right, only about one-third of people with Type 1 diabetes achieve optimal glucose control. This gap between effort and outcome is one of the biggest challenges in managing the disease.

Hybrid closed-loop (HCL) therapy represents a major shift in insulin delivery. These systems combine three key pieces: a continuous glucose monitor that reads blood sugar levels constantly, an insulin pump that delivers insulin under the skin, and an algorithm—a set of mathematical rules—that decides how much insulin to give and when.

In simple terms, HCL systems mimic what a working pancreas does automatically. When glucose rises, the system delivers more insulin. When it drops, the system reduces insulin flow. This happens without requiring the person to manually calculate and input doses throughout the day.

A 2024 systematic review of 28 randomized clinical trials found that all HCL systems significantly improved time in range—the percentage of time glucose stays in the target zone—compared to traditional insulin pump therapy without automation. On average, people using automated insulin delivery spent 11.74% more time in their target range.

When different HCL systems were compared head-to-head, the Minimed 780G achieved the highest time in range, performing better than the Control-IQ, Minimed 670G, CamAPS Fx, and DBLG-1 systems. However, all systems showed meaningful benefits over conventional therapy.

HCL systems also significantly reduced the time people spend with dangerously low blood sugar. The Minimed 670G and 780G showed the largest reductions in low blood sugar events compared to traditional pumps. Importantly, safety monitoring found that rates of severe hypoglycemia and diabetic ketoacidosis were similar across all system types.

Older adults with Type 1 diabetes face particular challenges: they are at higher risk for serious low blood sugar episodes, which can cause falls, heart problems, and other complications. A 2025 study of 82 people age 65 and older tested three types of insulin delivery: hybrid closed-loop, predictive low-glucose suspend (which alerts when low blood sugar is predicted), and traditional sensor-augmented pumps.

The hybrid closed-loop system was the most effective at reducing time spent with glucose below 70 mg/dL in this older population. It reduced dangerous lows by approximately 1 percentage point compared to traditional sensor-augmented pump therapy. Additionally, HCL improved time spent in the target range 70–180 mg/dL by nearly 9 percentage points. These improvements suggest HCL systems may be especially valuable for older adults seeking to reduce hypoglycemia risk while maintaining good glucose control.

Researchers are working to reduce the burden of HCL systems even further. Current systems require users to announce meals and exercise so the algorithm can anticipate glucose changes. New systems in development, such as the FLEX-AP system, aim to deliver fully automated insulin without requiring meal announcements.

These next-generation systems use advanced algorithms designed to detect unannounced meals and exercise automatically. They would still allow users to provide optional input if they choose, offering a balance between automation and personal control. While these systems are still in testing, they represent the direction of future diabetes technology: less work for people living with diabetes, and more time freed up for living their lives.

Origin: YouTube / CDEP (Video report). Evidence: Video report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.